1996
Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine
Ma J, Hine P, Clough E, Fish D, Coughlin R, Beltz G, Shew M. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 1996, 14: 1366-1374. PMID: 9004447, DOI: 10.1016/s0264-410x(96)00045-x.Peer-Reviewed Original ResearchConceptsCanine Lyme disease vaccineLyme disease vaccineDisease vaccineGeometric mean antibody titersInjection site swellingMean antibody titersTypical clinical signsMonths postchallengeVaccination timeSecond vaccinationBorrelial antigensSpirochetal antigensAntibody titersProtective efficacyControl beaglesAdverse reactionsVaccinated dogsClinical signsImmunological memoryLocal reactionsAntibody productionNormal beaglesVaccinatesLyme diseaseOsp A
1995
Protection of Dogs from Lyme Disease with a Vaccine Containing Outer Surface Protein (Osp) A, OspB, and the Saponin Adjuvant QS21
Coughlin R, Fish D, Mather T, Ma J, Pavia C, Bulger P. Protection of Dogs from Lyme Disease with a Vaccine Containing Outer Surface Protein (Osp) A, OspB, and the Saponin Adjuvant QS21. The Journal Of Infectious Diseases 1995, 171: 1049-1052. PMID: 7706788, DOI: 10.1093/infdis/171.4.1049.Peer-Reviewed Original ResearchConceptsProtection of dogsAdjuvant QS21Vaccinated dogsControl dogsLyme diseaseIxodes scapularisOuter surface protein ABorrelia burgdorferi infectionB. burgdorferiSurface protein ADogsBurgdorferi infectionVaccineScapularisQS21InfectionDiseaseProtectionXenodiagnosisBurgdorferiProtein AFeverSymptomsLimp